Design and Evaluation of 223Ra-Labeled and Anti-PSMA Targeted NaA Nanozeolites for Prostate Cancer Therapy—Part II. Toxicity, Pharmacokinetics and Biodistribution
Metastatic castration-resistant prostate cancer (mCRPC) is a progressive and incurable disease with poor prognosis for patients. Despite introduction of novel therapies, the mortality rate remains high. An attractive alternative for extension of the life of mCRPC patients is PSMA-based targeted radi...
Saved in:
| Published in: | International journal of molecular sciences Vol. 22; no. 11; p. 5702 |
|---|---|
| Main Authors: | , , , , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
MDPI
27-05-2021
MDPI AG |
| Subjects: | |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Metastatic castration-resistant prostate cancer (mCRPC) is a progressive and incurable disease with poor prognosis for patients. Despite introduction of novel therapies, the mortality rate remains high. An attractive alternative for extension of the life of mCRPC patients is PSMA-based targeted radioimmunotherapy. In this paper, we extended our in vitro study of 223Ra-labeled and PSMA-targeted NaA nanozeolites [223RaA-silane-PEG-D2B] by undertaking comprehensive preclinical in vitro and in vivo research. The toxicity of the new compound was evaluated in LNCaP C4-2, DU-145, RWPE-1 and HPrEC prostate cells and in BALB/c mice. The tissue distribution of 133Ba- and 223Ra-labeled conjugates was studied at different time points after injection in BALB/c and LNCaP C4-2 tumor-bearing BALB/c Nude mice. No obvious symptoms of antibody-free and antibody-functionalized nanocarriers cytotoxicity and immunotoxicity was found, while exposure to 223Ra-labeled conjugates resulted in bone marrow fibrosis, decreased the number of WBC and platelets and elevated serum concentrations of ALT and AST enzymes. Biodistribution studies revealed high accumulation of 223Ra-labeled conjugates in the liver, lungs, spleen and bone tissue. Nontargeted and PSMA-targeted radioconjugates exhibited a similar, marginal uptake in tumour lesions. In conclusion, despite the fact that NaA nanozeolites are safe carriers, the intravenous administration of NaA nanozeolite-based radioconjugates is dubious due to its high accumulation in the lungs, liver, spleen and bones. |
|---|---|
| AbstractList | Metastatic castration-resistant prostate cancer (mCRPC) is a progressive and incurable disease with poor prognosis for patients. Despite introduction of novel therapies, the mortality rate remains high. An attractive alternative for extension of the life of mCRPC patients is PSMA-based targeted radioimmunotherapy. In this paper, we extended our in vitro study of 223Ra-labeled and PSMA-targeted NaA nanozeolites [223RaA-silane-PEG-D2B] by undertaking comprehensive preclinical in vitro and in vivo research. The toxicity of the new compound was evaluated in LNCaP C4-2, DU-145, RWPE-1 and HPrEC prostate cells and in BALB/c mice. The tissue distribution of 133Ba- and 223Ra-labeled conjugates was studied at different time points after injection in BALB/c and LNCaP C4-2 tumor-bearing BALB/c Nude mice. No obvious symptoms of antibody-free and antibody-functionalized nanocarriers cytotoxicity and immunotoxicity was found, while exposure to 223Ra-labeled conjugates resulted in bone marrow fibrosis, decreased the number of WBC and platelets and elevated serum concentrations of ALT and AST enzymes. Biodistribution studies revealed high accumulation of 223Ra-labeled conjugates in the liver, lungs, spleen and bone tissue. Nontargeted and PSMA-targeted radioconjugates exhibited a similar, marginal uptake in tumour lesions. In conclusion, despite the fact that NaA nanozeolites are safe carriers, the intravenous administration of NaA nanozeolite-based radioconjugates is dubious due to its high accumulation in the lungs, liver, spleen and bones. Metastatic castration-resistant prostate cancer (mCRPC) is a progressive and incurable disease with poor prognosis for patients. Despite introduction of novel therapies, the mortality rate remains high. An attractive alternative for extension of the life of mCRPC patients is PSMA-based targeted radioimmunotherapy. In this paper, we extended our in vitro study of 223 Ra-labeled and PSMA-targeted NaA nanozeolites [ 223 RaA-silane-PEG-D2B] by undertaking comprehensive preclinical in vitro and in vivo research. The toxicity of the new compound was evaluated in LNCaP C4-2, DU-145, RWPE-1 and HPrEC prostate cells and in BALB/c mice. The tissue distribution of 133 Ba- and 223 Ra-labeled conjugates was studied at different time points after injection in BALB/c and LNCaP C4-2 tumor-bearing BALB/c Nude mice. No obvious symptoms of antibody-free and antibody-functionalized nanocarriers cytotoxicity and immunotoxicity was found, while exposure to 223 Ra-labeled conjugates resulted in bone marrow fibrosis, decreased the number of WBC and platelets and elevated serum concentrations of ALT and AST enzymes. Biodistribution studies revealed high accumulation of 223 Ra-labeled conjugates in the liver, lungs, spleen and bone tissue. Nontargeted and PSMA-targeted radioconjugates exhibited a similar, marginal uptake in tumour lesions. In conclusion, despite the fact that NaA nanozeolites are safe carriers, the intravenous administration of NaA nanozeolite-based radioconjugates is dubious due to its high accumulation in the lungs, liver, spleen and bones. |
| Author | Mikołajczak, Renata Lankoff, Anna Walczak, Rafał Tomczyk, Kamil Kruszewski, Marcin Fracasso, Giulio Karczmarczyk, Urszula Garnuszek, Piotr Brzóska, Kamil Czerwińska, Malwina |
| AuthorAffiliation | 3 Centre of Radiochemistry and Nuclear Chemistry, Institute of Nuclear Chemistry and Technology, Dorodna 16, 03-195 Warsaw, Poland; r.walczak@ichtj.waw.pl 6 Department of Molecular Biology and Translational Research, Institute of Rural Health, Jaczewskiego 2, 20-090 Lublin, Poland 4 National Centre for Nuclear Research, Radioisotope Centre POLATOM, Sołtana 7, 05-400 Otwock, Poland; urszula.karczmarczyk@polatom.pl (U.K.); Kamil.Tomczyk@polatom.pl (K.T.); Piotr.Garnuszek@polatom.pl (P.G.); renata.mikolajczak@polatom.pl (R.M.) 5 Department of Medicine, University of Verona, 37129 Verona, Italy; giulio.fracasso@univr.it 1 Centre for Radiobiology and Biological Dosimetry, Institute of Nuclear Chemistry and Technology, Dorodna 16, 03-195 Warsaw, Poland; m.wasilewska@ichtj.waw.pl (M.C.); K.Brzoska@ichtj.waw.pl (K.B.); m.kruszewski@ichtj.waw.pl (M.K.) 2 Department of Medical Biology, Institute of Biology, Jan Kochanowski University, Uniwersytecka 7, 24-406 Kielce, Poland |
| AuthorAffiliation_xml | – name: 5 Department of Medicine, University of Verona, 37129 Verona, Italy; giulio.fracasso@univr.it – name: 2 Department of Medical Biology, Institute of Biology, Jan Kochanowski University, Uniwersytecka 7, 24-406 Kielce, Poland – name: 1 Centre for Radiobiology and Biological Dosimetry, Institute of Nuclear Chemistry and Technology, Dorodna 16, 03-195 Warsaw, Poland; m.wasilewska@ichtj.waw.pl (M.C.); K.Brzoska@ichtj.waw.pl (K.B.); m.kruszewski@ichtj.waw.pl (M.K.) – name: 4 National Centre for Nuclear Research, Radioisotope Centre POLATOM, Sołtana 7, 05-400 Otwock, Poland; urszula.karczmarczyk@polatom.pl (U.K.); Kamil.Tomczyk@polatom.pl (K.T.); Piotr.Garnuszek@polatom.pl (P.G.); renata.mikolajczak@polatom.pl (R.M.) – name: 6 Department of Molecular Biology and Translational Research, Institute of Rural Health, Jaczewskiego 2, 20-090 Lublin, Poland – name: 3 Centre of Radiochemistry and Nuclear Chemistry, Institute of Nuclear Chemistry and Technology, Dorodna 16, 03-195 Warsaw, Poland; r.walczak@ichtj.waw.pl |
| Author_xml | – sequence: 1 givenname: Anna orcidid: 0000-0002-6661-7949 surname: Lankoff fullname: Lankoff, Anna – sequence: 2 givenname: Malwina surname: Czerwińska fullname: Czerwińska, Malwina – sequence: 3 givenname: Rafał surname: Walczak fullname: Walczak, Rafał – sequence: 4 givenname: Urszula orcidid: 0000-0001-7841-3946 surname: Karczmarczyk fullname: Karczmarczyk, Urszula – sequence: 5 givenname: Kamil orcidid: 0000-0002-5844-1541 surname: Tomczyk fullname: Tomczyk, Kamil – sequence: 6 givenname: Kamil orcidid: 0000-0001-7310-5100 surname: Brzóska fullname: Brzóska, Kamil – sequence: 7 givenname: Giulio orcidid: 0000-0003-3024-0307 surname: Fracasso fullname: Fracasso, Giulio – sequence: 8 givenname: Piotr orcidid: 0000-0003-0650-1992 surname: Garnuszek fullname: Garnuszek, Piotr – sequence: 9 givenname: Renata orcidid: 0000-0002-6882-751X surname: Mikołajczak fullname: Mikołajczak, Renata – sequence: 10 givenname: Marcin orcidid: 0000-0003-4554-8566 surname: Kruszewski fullname: Kruszewski, Marcin |
| BookMark | eNpVkUtuE0EQhlsoiDxgxwH6AJnQz3lskEwSwJIBC8x6VNNTbbcZd1vd7Qiz4hAcgZNxEiY2QsmiVKW_VF-9zsmJDx4JecnZlZQNe-XWmyQE57pi4gk540qIgrGyOnkQn5LzlNaMCSl084ycSsUqXmt1Rn7fYHJLT8H39PYOhh1kFzwNlgohP0Mxgw4H7A_5ic-umH_5MKELiEvMo_wRJqP58APD4DImakOk8xhShoz0GrzBSBcrjLDd__n5aw4x0-n0ii7Cd2dc3l_S-QriBkz45jxmZ9Kh0xsXepdydN3ufpzn5KmFIeGLf_6CfH17u7h-X8w-vZteT2aFkbrKBZhxWN5oJZms-1LpimOJlhvouWiaSmpmGimQQW2YspozjpXQvFNWVrqx8oJMj9w-wLrdRreBuG8DuPYghLhsxwWcGbDlfTfeFXldIVMGAaziSkpR2oZ3pepH1usja7vrNtgb9DnC8Aj6OOPdql2Gu7bmTV0yPQIujwAznjNFtP9rOWvvP98-_Lz8C2XjpIk |
| CitedBy_id | crossref_primary_10_2174_0929867329666220420131836 crossref_primary_10_3390_ijms25010664 crossref_primary_10_3389_fimmu_2023_1265751 crossref_primary_10_1186_s41181_024_00266_y crossref_primary_10_3390_ph16020315 crossref_primary_10_1186_s41181_023_00220_4 crossref_primary_10_1053_j_semnuclmed_2023_06_007 crossref_primary_10_3390_molecules28104122 crossref_primary_10_1186_s41181_022_00161_4 |
| Cites_doi | 10.2967/jnumed.115.166173 10.1186/s41181-018-0042-3 10.1002/cmmi.1596 10.1039/D0SC06867E 10.1007/s11051-016-3615-7 10.1007/s11051-013-2082-7 10.1016/j.ajur.2018.11.005 10.3109/17435390.2011.587901 10.1002/smll.201603847 10.1002/jlcr.3610 10.1186/1477-3155-11-36 10.1016/j.eururo.2021.03.004 10.1039/C9RA08953E 10.7150/thno.37204 10.3390/cells7090122 10.1016/j.jbiosc.2011.01.017 10.3390/molecules25051025 10.1007/s11523-020-00720-2 10.1021/pr050420t 10.1053/j.semnuclmed.2019.11.005 10.1038/cdd.2011.158 10.1016/j.ymeth.2006.07.010 10.3390/ph13100272 10.1016/S0002-9440(10)65006-7 10.1002/pros.23642 10.1186/s11671-016-1334-8 10.1016/j.bbcan.2020.188450 10.2174/1874471011104030177 10.1259/bjr.20140752 10.1053/j.semnuclmed.2020.02.004 10.1016/j.addr.2018.07.007 10.1016/j.mcna.2013.09.005 10.1016/j.nucmedbio.2003.11.004 10.1016/j.ejca.2013.01.024 10.2967/jnumed.115.171397 10.3390/jpm11020124 10.2174/1874471011205030221 10.1016/j.nucmedbio.2016.11.005 10.1016/j.radonc.2015.07.036 10.3390/biomedicines8120602 10.1038/s41391-021-00349-w 10.1016/j.biotechadv.2017.08.003 10.1016/j.ecoenv.2020.111496 10.1038/s41467-017-00600-w 10.3390/molecules25071743 10.3390/ma13173875 10.1021/mp300016p 10.1016/j.jconrel.2019.04.041 10.1134/S1066362211040126 10.1002/jmrs.227 10.1038/s41585-019-0251-x 10.1200/EDBK_239187 10.2147/OTT.S216829 |
| ContentType | Journal Article |
| Copyright | 2021 by the authors. 2021 |
| Copyright_xml | – notice: 2021 by the authors. 2021 |
| DBID | AAYXX CITATION 5PM DOA |
| DOI | 10.3390/ijms22115702 |
| DatabaseName | CrossRef PubMed Central (Full Participant titles) Directory of Open Access Journals |
| DatabaseTitle | CrossRef |
| DatabaseTitleList | CrossRef |
| Database_xml | – sequence: 1 dbid: DOA name: Directory of Open Access Journals url: http://www.doaj.org/ sourceTypes: Open Website |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Biology |
| EISSN | 1422-0067 |
| ExternalDocumentID | oai_doaj_org_article_1db067e187e04ceaaf4143326f91b64d 10_3390_ijms22115702 |
| GroupedDBID | --- 29J 2WC 3V. 53G 5GY 5VS 7X7 88E 8FE 8FG 8FH 8FI 8FJ 8G5 A8Z AADQD AAFWJ AAHBH AAYXX ABDBF ABJCF ABUWG ACGFO ACIHN ACIWK ACPRK ADBBV AEAQA AENEX AFKRA AFZYC ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS AZQEC BAWUL BBNVY BCNDV BENPR BHPHI BPHCQ BVXVI CCPQU CITATION CS3 D1I DIK DU5 DWQXO E3Z EBD EBS EJD ESTFP ESX F5P FRP FYUFA GNUQQ GROUPED_DOAJ GUQSH GX1 HCIFZ HH5 HMCUK HYE IAO ITC KB. KQ8 LK8 M1P M2O M48 M7P MODMG M~E O5R O5S OK1 P2P PDBOC PIMPY PQQKQ PROAC PSQYO RIG RNS RPM TR2 TUS UKHRP ~8M 5PM AFPKN |
| ID | FETCH-LOGICAL-c357t-acabe19543038d64571e6ef1cad12997350c932e0a8c04f5101e7251b4f3759f3 |
| IEDL.DBID | RPM |
| ISSN | 1422-0067 1661-6596 |
| IngestDate | Tue Oct 22 15:07:22 EDT 2024 Tue Sep 17 21:23:15 EDT 2024 Fri Nov 22 03:33:38 EST 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 11 |
| Language | English |
| License | Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c357t-acabe19543038d64571e6ef1cad12997350c932e0a8c04f5101e7251b4f3759f3 |
| ORCID | 0000-0002-5844-1541 0000-0001-7310-5100 0000-0003-0650-1992 0000-0002-6661-7949 0000-0003-3024-0307 0000-0003-4554-8566 0000-0001-7841-3946 0000-0002-6882-751X |
| OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8198605/ |
| PMID | 34071854 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_1db067e187e04ceaaf4143326f91b64d pubmedcentral_primary_oai_pubmedcentral_nih_gov_8198605 crossref_primary_10_3390_ijms22115702 |
| PublicationCentury | 2000 |
| PublicationDate | 20210527 |
| PublicationDateYYYYMMDD | 2021-05-27 |
| PublicationDate_xml | – month: 5 year: 2021 text: 20210527 day: 27 |
| PublicationDecade | 2020 |
| PublicationTitle | International journal of molecular sciences |
| PublicationYear | 2021 |
| Publisher | MDPI MDPI AG |
| Publisher_xml | – name: MDPI – name: MDPI AG |
| References | ref_50 Bertrand (ref_46) 2017; 8 Golombek (ref_55) 2018; 130 Kukleva (ref_20) 2020; 10 Emmett (ref_51) 2017; 64 Chinen (ref_47) 2017; 13 Chattopadhyay (ref_60) 2012; 9 ref_57 Jonasdottir (ref_17) 2006; 26 Kratochwil (ref_8) 2020; 50 Malenge (ref_19) 2018; 61 Pai (ref_34) 2020; 1874 Brito (ref_13) 2020; 50 Dhaliwal (ref_58) 2019; 9 Mohammadpour (ref_31) 2019; 304 Piotrowska (ref_23) 2017; 47 Piotrowska (ref_22) 2013; 15 Franssen (ref_54) 2015; 10 Henriksen (ref_14) 2003; 44 ref_25 ref_24 Vogler (ref_35) 2012; 19 Holzwarth (ref_49) 2018; 3 ref_21 ref_64 ref_63 Hashizume (ref_56) 2000; 156 Xu (ref_37) 2019; 12 Zalutsky (ref_9) 2012; 4 Shishkin (ref_11) 2011; 53 Morris (ref_12) 2019; 16 Kihara (ref_29) 2011; 111 Vanitha (ref_39) 2020; 10 Morgenstern (ref_10) 2012; 5 Larsen (ref_53) 2006; 20 Mokhodoeva (ref_18) 2016; 18 Sun (ref_42) 2021; 208 ref_32 Dorff (ref_52) 2019; 39 Bolkestein (ref_59) 2016; 57 ref_38 Chowdhury (ref_2) 2020; 15 Frigerio (ref_62) 2013; 49 Woreta (ref_41) 2014; 98 Miyahira (ref_6) 2018; 78 Jain (ref_40) 2017; 35 Alge (ref_26) 2006; 5 Kratochwil (ref_4) 2016; 57 Dong (ref_1) 2019; 6 Baldi (ref_44) 2014; 9 ref_45 Henriksen (ref_16) 2004; 31 Turner (ref_48) 2015; 88 Engin (ref_30) 2018; 2 Wang (ref_36) 2018; 15 Abou (ref_15) 2021; 12 ref_3 Baken (ref_33) 2007; 41 Trip (ref_43) 2015; 116 Piotrowska (ref_27) 2016; 11 ref_5 Thomassen (ref_28) 2012; 6 ref_7 Yang (ref_61) 2013; 11 |
| References_xml | – volume: 57 start-page: 601 year: 2016 ident: ref_59 article-title: Investigation of factors determining the enhanced permeability and retention effect in subcutaneous xenografts publication-title: J. Nucl. Med. doi: 10.2967/jnumed.115.166173 contributor: fullname: Bolkestein – volume: 3 start-page: 9 year: 2018 ident: ref_49 article-title: A random walk approach to estimate the confinement of α-particle emitters in nanoparticles for targeted radionuclide therapy publication-title: EJNMMI Radiopharm. Chem. doi: 10.1186/s41181-018-0042-3 contributor: fullname: Holzwarth – volume: 10 start-page: 28 year: 2015 ident: ref_54 article-title: Targeting human prostate cancer with 111In-labeled D2B IgG, F(ab′)2 and Fab fragments in nude mice with PSMA-expressing xenografts publication-title: Contrast Media Mol. Imaging doi: 10.1002/cmmi.1596 contributor: fullname: Franssen – volume: 12 start-page: 3733 year: 2021 ident: ref_15 article-title: Towards the stable chelation of radium for biomedical applications with an 18-membered macrocyclic ligand publication-title: Chem. Sci. doi: 10.1039/D0SC06867E contributor: fullname: Abou – volume: 18 start-page: 301 year: 2016 ident: ref_18 article-title: Study of 223Ra uptake mechanism by Fe3O4 nanoparticles: Towards new prospective theranostic SPIONs publication-title: J. Nanopart. Res. doi: 10.1007/s11051-016-3615-7 contributor: fullname: Mokhodoeva – volume: 15 start-page: 2082 year: 2013 ident: ref_22 article-title: Functionalized NaA nanozeolites labeled with224,225Ra for targeted alpha therapy publication-title: J. Nanopart. Res. doi: 10.1007/s11051-013-2082-7 contributor: fullname: Piotrowska – volume: 6 start-page: 26 year: 2019 ident: ref_1 article-title: Metastatic prostate cancer remains incurable, why? publication-title: Asian J. Urol. doi: 10.1016/j.ajur.2018.11.005 contributor: fullname: Dong – volume: 6 start-page: 472 year: 2012 ident: ref_28 article-title: Investigation of the cytotoxicity of nanozeolites A and y publication-title: Nanotoxicology doi: 10.3109/17435390.2011.587901 contributor: fullname: Thomassen – volume: 13 start-page: 1603847 year: 2017 ident: ref_47 article-title: The Impact of Protein Corona Formation on the Macrophage Cellular Uptake and Biodistribution of Spherical Nucleic Acids publication-title: Small doi: 10.1002/smll.201603847 contributor: fullname: Chinen – volume: 61 start-page: 472 year: 2018 ident: ref_19 article-title: Ra-224 labeling of calcium carbonate microparticles for internal α-therapy: Preparation, stability, and biodistribution in mice publication-title: J. Label. Compd. Radiopharm. doi: 10.1002/jlcr.3610 contributor: fullname: Malenge – volume: 11 start-page: 36 year: 2013 ident: ref_61 article-title: The biodistribution of self-assembling protein nanoparticles shows they are promising vaccine platforms publication-title: J. Nanobiotechnol. doi: 10.1186/1477-3155-11-36 contributor: fullname: Yang – ident: ref_5 doi: 10.1016/j.eururo.2021.03.004 – volume: 10 start-page: 3659 year: 2020 ident: ref_20 article-title: Study of 223ra uptake mechanism on hydroxyapatite and titanium dioxide nanoparticles as a function of ph publication-title: RSC Adv. doi: 10.1039/C9RA08953E contributor: fullname: Kukleva – volume: 9 start-page: 26 year: 2019 ident: ref_58 article-title: Improving accessibility of EPR-insensitive tumor phenotypes using EPR-adaptive strategies: Designing a new perspective in nanomedicine delivery publication-title: Theranostics doi: 10.7150/thno.37204 contributor: fullname: Dhaliwal – ident: ref_32 doi: 10.3390/cells7090122 – volume: 9 start-page: 3037 year: 2014 ident: ref_44 article-title: In vivo anticancer evaluation of the hyperthermic efficacy of anti-human epidermal growth factor receptor-targeted PEG-based nanocarrier containing magnetic nanoparticles publication-title: Int. J. Nanomed. contributor: fullname: Baldi – volume: 111 start-page: 725 year: 2011 ident: ref_29 article-title: Effect of composition, morphology and size of nanozeolite on its in vitro cytotoxicity publication-title: J. Biosci. Bioeng. doi: 10.1016/j.jbiosc.2011.01.017 contributor: fullname: Kihara – volume: 10 start-page: 3659 year: 2020 ident: ref_39 article-title: Study of 223Ra uptake mechanism by Fe3O4 nanoparticles: Towards new prospective theranostic SPIONs publication-title: J. Nanopart. Res. contributor: fullname: Vanitha – ident: ref_45 doi: 10.3390/molecules25051025 – volume: 15 start-page: 301 year: 2020 ident: ref_2 article-title: Real-World Outcomes in First-Line Treatment of Metastatic Castration-Resistant Prostate Cancer: The Prostate Cancer Registry publication-title: Target. Oncol. doi: 10.1007/s11523-020-00720-2 contributor: fullname: Chowdhury – volume: 5 start-page: 862 year: 2006 ident: ref_26 article-title: Differential protein profiling of primary versus immortalized human RPE cells identifies expression patterns associated with cytoskeletal remodeling and cell survival publication-title: J. Proteome Res. doi: 10.1021/pr050420t contributor: fullname: Alge – volume: 50 start-page: 177 year: 2020 ident: ref_13 article-title: Radium-223 as an Approved Modality for Treatment of Bone Metastases publication-title: Semin. Nucl. Med. doi: 10.1053/j.semnuclmed.2019.11.005 contributor: fullname: Brito – volume: 26 start-page: 2841 year: 2006 ident: ref_17 article-title: First in vivo evaluation of liposome-encapsulated 223Ra as a potential alpha-particle-emitting cancer therapeutic agent publication-title: Anticancer Res. contributor: fullname: Jonasdottir – volume: 19 start-page: 67 year: 2012 ident: ref_35 article-title: BCL2A1: The underdog in the BCL2 family publication-title: Cell Death Differ. doi: 10.1038/cdd.2011.158 contributor: fullname: Vogler – volume: 2 start-page: 239784731875557 year: 2018 ident: ref_30 article-title: The impact of immunotoxicity in evaluation of the nanomaterials safety publication-title: Toxicol. Res. Appl. contributor: fullname: Engin – volume: 41 start-page: 132 year: 2007 ident: ref_33 article-title: van Toxicogenomics in the assessment of immunotoxicity publication-title: Methods doi: 10.1016/j.ymeth.2006.07.010 contributor: fullname: Baken – ident: ref_21 doi: 10.3390/ph13100272 – volume: 156 start-page: 1363 year: 2000 ident: ref_56 article-title: Openings between defective endothelial cells explain tumor vessel leakiness publication-title: Am. J. Pathol. doi: 10.1016/S0002-9440(10)65006-7 contributor: fullname: Hashizume – volume: 78 start-page: 775 year: 2018 ident: ref_6 article-title: Meeting report from the Prostate Cancer Foundation PSMA-directed radionuclide scientific working group publication-title: Prostate doi: 10.1002/pros.23642 contributor: fullname: Miyahira – volume: 11 start-page: 123 year: 2016 ident: ref_27 article-title: Effect of Surface Functionalization on the Cellular Uptake and Toxicity of Nanozeolite A publication-title: Nanoscale Res. Lett. doi: 10.1186/s11671-016-1334-8 contributor: fullname: Piotrowska – volume: 1874 start-page: 188450 year: 2020 ident: ref_34 article-title: HOX genes and the NF-κB pathway: A convergence of developmental biology, inflammation and cancer biology publication-title: Biochim. Biophys. Acta Rev. Cancer doi: 10.1016/j.bbcan.2020.188450 contributor: fullname: Pai – volume: 4 start-page: 177 year: 2012 ident: ref_9 article-title: Astatine-211: Production and Availability publication-title: Curr. Radiopharm. doi: 10.2174/1874471011104030177 contributor: fullname: Zalutsky – volume: 88 start-page: 20140752 year: 2015 ident: ref_48 article-title: 223Ra and other bone-targeting radiopharmaceuticals? The translation of radiation biology into clinical practice publication-title: Br. J. Radiol. doi: 10.1259/bjr.20140752 contributor: fullname: Turner – volume: 50 start-page: 133 year: 2020 ident: ref_8 article-title: 225Ac-PSMA-617 for Therapy of Prostate Cancer publication-title: Semin. Nucl. Med. doi: 10.1053/j.semnuclmed.2020.02.004 contributor: fullname: Kratochwil – ident: ref_63 – volume: 130 start-page: 17 year: 2018 ident: ref_55 article-title: Tumor targeting via EPR: Strategies to enhance patient responses publication-title: Adv. Drug Deliv. Rev. doi: 10.1016/j.addr.2018.07.007 contributor: fullname: Golombek – volume: 20 start-page: 325 year: 2006 ident: ref_53 article-title: Radiotoxicity of the alpha-emitting bone-seeker 223Ra injected intravenously into mice: Histology, clinical chemistry and hematology publication-title: In Vivo contributor: fullname: Larsen – volume: 98 start-page: 1 year: 2014 ident: ref_41 article-title: Evaluation of abnormal liver tests publication-title: Med. Clin. N. Am. doi: 10.1016/j.mcna.2013.09.005 contributor: fullname: Woreta – volume: 31 start-page: 441 year: 2004 ident: ref_16 article-title: Sterically stabilized liposomes as a carrier for α-emitting radium and actinium radionuclides publication-title: Nucl. Med. Biol. doi: 10.1016/j.nucmedbio.2003.11.004 contributor: fullname: Henriksen – volume: 49 start-page: 2223 year: 2013 ident: ref_62 article-title: A single-chain fragment against prostate specific membrane antigen as a tool to build theranostic reagents for prostate cancer publication-title: Eur. J. Cancer doi: 10.1016/j.ejca.2013.01.024 contributor: fullname: Frigerio – volume: 57 start-page: 1170 year: 2016 ident: ref_4 article-title: PSMA-targeted radionuclide therapy of metastatic castration-resistant prostate cancer with 177Lu-Labeled PSMA-617 publication-title: J. Nucl. Med. doi: 10.2967/jnumed.115.171397 contributor: fullname: Kratochwil – ident: ref_25 – ident: ref_50 – ident: ref_57 doi: 10.3390/jpm11020124 – volume: 5 start-page: 221 year: 2012 ident: ref_10 article-title: Bismuth-213 and Actinium-225—Generator Performance and Evolving Therapeutic Applications of Two Generator-Derived Alpha-Emitting Radioisotopes publication-title: Curr. Radiopharm. doi: 10.2174/1874471011205030221 contributor: fullname: Morgenstern – volume: 47 start-page: 10 year: 2017 ident: ref_23 article-title: Nanozeolite bioconjugates labeled with 223Ra for targeted alpha therapy publication-title: Nucl. Med. Biol. doi: 10.1016/j.nucmedbio.2016.11.005 contributor: fullname: Piotrowska – volume: 116 start-page: 239 year: 2015 ident: ref_43 article-title: Radiation-induced dose-dependent changes of the spleen following postoperative chemoradiotherapy for gastric cancer publication-title: Radiother. Oncol. doi: 10.1016/j.radonc.2015.07.036 contributor: fullname: Trip – ident: ref_38 doi: 10.3390/biomedicines8120602 – ident: ref_7 doi: 10.1038/s41391-021-00349-w – volume: 35 start-page: 889 year: 2017 ident: ref_40 article-title: In-vitro in-vivo correlation (IVIVC) in nanomedicine: Is protein corona the missing link? publication-title: Biotechnol. Adv. doi: 10.1016/j.biotechadv.2017.08.003 contributor: fullname: Jain – volume: 208 start-page: 111496 year: 2021 ident: ref_42 article-title: Metabolomic characteristics of hepatotoxicity in rats induced by silica nanoparticles publication-title: Ecotoxicol. Environ. Saf. doi: 10.1016/j.ecoenv.2020.111496 contributor: fullname: Sun – volume: 8 start-page: 777 year: 2017 ident: ref_46 article-title: Mechanistic understanding of in vivo protein corona formation on polymeric nanoparticles and impact on pharmacokinetics publication-title: Nat. Commun. doi: 10.1038/s41467-017-00600-w contributor: fullname: Bertrand – ident: ref_3 doi: 10.3390/molecules25071743 – ident: ref_64 – ident: ref_24 doi: 10.3390/ma13173875 – volume: 9 start-page: 2168 year: 2012 ident: ref_60 article-title: Role of antibody-mediated tumor targeting and route of administration in nanoparticle tumor accumulation in vivo publication-title: Mol. Pharm. doi: 10.1021/mp300016p contributor: fullname: Chattopadhyay – volume: 304 start-page: 216 year: 2019 ident: ref_31 article-title: Subchronic toxicity of silica nanoparticles as a function of size and porosity publication-title: J. Control. Release doi: 10.1016/j.jconrel.2019.04.041 contributor: fullname: Mohammadpour – volume: 44 start-page: 252 year: 2003 ident: ref_14 article-title: Targeting of osseous sites with α-emitting 223Ra: Comparison with the β-emitter 89Sr in mice publication-title: J. Nucl. Med. contributor: fullname: Henriksen – volume: 53 start-page: 404 year: 2011 ident: ref_11 article-title: Extraction generator of 223Ra for nuclear medicine publication-title: Radiochemistry doi: 10.1134/S1066362211040126 contributor: fullname: Shishkin – volume: 64 start-page: 52 year: 2017 ident: ref_51 article-title: Lutetium 177 PSMA radionuclide therapy for men with prostate cancer: A review of the current literature and discussion of practical aspects of therapy publication-title: J. Med. Radiat. Sci. doi: 10.1002/jmrs.227 contributor: fullname: Emmett – volume: 16 start-page: 745 year: 2019 ident: ref_12 article-title: Radium-223 mechanism of action: Implications for use in treatment combinations publication-title: Nat. Rev. Urol. doi: 10.1038/s41585-019-0251-x contributor: fullname: Morris – volume: 39 start-page: 321 year: 2019 ident: ref_52 article-title: The Evolving Role of Prostate-Specific Membrane Antigen–Based Diagnostics and Therapeutics in Prostate Cancer publication-title: Am. Soc. Clin. Oncol. Educ. B. doi: 10.1200/EDBK_239187 contributor: fullname: Dorff – volume: 15 start-page: 3028 year: 2018 ident: ref_36 article-title: Inhibition of prostate cancer DU145 cell growth with small interfering RNA targeting the SATB1 gene publication-title: Exp. Ther. Med. contributor: fullname: Wang – volume: 12 start-page: 11255 year: 2019 ident: ref_37 article-title: Demethylation and overexpression of CSF2 are involved in immune response, chemotherapy resistance, and poor prognosis in colorectal cancer publication-title: OncoTargets Ther. doi: 10.2147/OTT.S216829 contributor: fullname: Xu |
| SSID | ssj0023259 |
| Score | 2.415125 |
| Snippet | Metastatic castration-resistant prostate cancer (mCRPC) is a progressive and incurable disease with poor prognosis for patients. Despite introduction of novel... |
| SourceID | doaj pubmedcentral crossref |
| SourceType | Open Website Open Access Repository Aggregation Database |
| StartPage | 5702 |
| SubjectTerms | D2B antibodies prostate cancer PSMA-targeted radioligand therapy radium-223 toxicity zeolite nanoparticles |
| SummonAdditionalLinks | – databaseName: Directory of Open Access Journals dbid: DOA link: http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NThsxELYoEhKXqrRFhELlQ3vDZf233j2GJAgkQBGkUm8rxz8iVN0gEqSWEw_BI_BkfZLOeDcR6aWXHvZi764tz6znm9Xnbwj5JEqnReSBZa40TFknmY05MgFyHhSS2pKoz8mVufhW9Acok7Ms9YWcsEYeuFm4Q-7HsKEGXpiQKResjYqj5lYeSz7OlU-7b2YWyVSbakmRyqRxiD4s12XeUN4lJPiHk5sfMyFQY6b9lbIIRkmz_29u5Itgc_yGvG5RIu02s9sia6F-SzaaupG_3pHnfuJdUFt7OljKddNppBCGLy07s2OIJj71d-v5hA2vzrt0lEjf0Hxhu3DV04eA5LcwowBc6RCPfwDwpD30gzs6auQGfj8-DWGR6OnpFzqa_pw4QO0HdNgKXn8HjIo6z2kkmJ5HGd62gtZ78vV4MOqdsLbcAnNSmzmzDiaHAnAQ1QqfK214yEPkznoABaWRGuwpRchs4TIV8WMOBuDRWEVpdBnlNlmvp3XYIVQrm2ldyCw4r7yCJyLXhZAebV9q0SGfF-te3TaqGhVkI2if6qV9OuQIjbK8B7WwUwN4SNV6SPUvD-kQs2LSlbet9tST66SwDTCpgDxv938M_4FsCuTBZHj2b4-sz-_uwz55NfP3H5PP_gFmifHr priority: 102 providerName: Directory of Open Access Journals |
| Title | Design and Evaluation of 223Ra-Labeled and Anti-PSMA Targeted NaA Nanozeolites for Prostate Cancer Therapy—Part II. Toxicity, Pharmacokinetics and Biodistribution |
| URI | https://pubmed.ncbi.nlm.nih.gov/PMC8198605 https://doaj.org/article/1db067e187e04ceaaf4143326f91b64d |
| Volume | 22 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3LjtMwFLXoSEhs0PASZaDyAnakjWM7Tpal09FUMKOIKRK7yPGDCdBk1HYkYMVH8Al8GV_CvU46mrJkkY0TJ5bvjc650vG5hLxMciMTz1wUm1xFQhseaZ-iEiBlTqCoLZj6nF6o84_Z8RxtcuTuLEwQ7ZuqHjdfV-OmvgzayquVmex0YpPibAYolgENnwzIALjhrkTvqywOhL5TuHOo5yf159UmSdBSJsbONRwLmEyKPRgKbv3_qiJvwczJIbnf80M67dbxgNxxzUNyt-sY-f0R-X0cFBcU6n86vzHqpq2nAMDvdfROV4AjNtyfNts6Ki7OpnQZ5N4wfK6ncDXtD4eyN7ehQFlpgQc_gHLSGWbAmi47o4E_P38VsB10sRjTZfutNsDXX9Oit7r-AuwUHZ7Dl2B5Fg14-95Zj8mHk_lydhr1jRYiw6XaRtrA4tD6DfAss6mQirnUeWa0BTqQKy4hkjxxsc5MLDz-xk4BMaqE50rmnj8hB03buKeESqFjKTMeO2OFFTDDM5kl3GLUc5kMyavdvpdXnZ9GCXUIhqq8HaoheYNBuXkGXbDDQLv-VPa5UDJbAdg6likXC-O09oKhH1vqc1alwg6J2gvp3tv270CqBW_tPrWe_ffMI3IvQdlLjEf9npOD7fravSCDjb0eAWNfvB2Fqn8UcvYvvvPydA |
| link.rule.ids | 230,315,729,782,786,866,887,2107,27934,27935,53802,53804 |
| linkProvider | National Library of Medicine |
| linkToHtml | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9NAEF7RIgQX3qjhuQe44cT27vpxDGmqRCSRRY3EzVrvA0yJXSWpBJz6I_oT-sv6S5hZO1XDsQdfdr32SDP2fCN98w0h78NUidAGxvNVGntcKuZJGyETIAoMR1KbE_WZHMeLb8nhGGVyxLYXxpH2VVn161_Lfl39cNzK06UabHlig2w-giyWAAwf7JG78L364bZI7-osBpC-5bgzqOgH1c_lOgxRVMbH2TUMS5hE8J1E5PT6_-dF3kg0R49uaeJj8rBDlnTYbj8hd0z9lNxrZ03-eUYuDx1Xg8pa0_G1xDdtLIXU_UV6M1lCBtJuf1hvKi87ng9p7ojisLyQQ7jq5q9BwpxZUwC7NMOWEQCrdISxs6J5K1FwdX6RgZV0Ou3TvPldKUD6H2nWiWSfAK5FbWj3JjBPo3RvN3XrOfl6NM5HE68b0eApJuKNJxUYh6JxkAkTHXERByYyNlBSA5BIYyYgBlhofJkon1v8AZgYIFXJLYtFatkLsl83tTkgVHDpC5Ew3yjNNYcTNhBJyDTGSyrCHvmw9Vdx2ipxFFDBoIuLmy7ukU_ozOt7UD_bLTSr70XnoiLQJaRpEySx8bkyUloeoJJbZNOgjLjukXgnFHaetrsDEeBUuTuPv7z1yXfk_iSfz4rZdPH5FXkQInnGx4bB12R_szozb8jeWp-9dbH-D4CxBiQ |
| linkToPdf | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3JjtNAEG0xg0Bc2BFh7QPccLx0t5djyKKJmIksJkjcrHYvjAdiR0lGAk7zEfMJfBlfQlXbiSYc4eBLL3ZJVe16Jb1-RcibKFMisqHxApUlHpeKedLGyASIQ8OR1OZEfY5Ok9nndDRGmZxdqy9H2ldl1a-_Lfp1dea4lcuF8rc8MT8_GUIWSwGG-0tt_QNyE85swLeFeldrMYD1Lc-dQVXvV-eLdRShsEyA_WsYljGp4HvJyGn2_82NvJZsJvf-w8z75G6HMOmgXfKA3DD1Q3Kr7Tn54xH5NXKcDSprTcc7qW_aWAop_KP0jmUJmUi7-UG9qbz89GRA544wDsMzOYCnbn4aJM6ZNQXQS3O8OgKglQ4xhlZ03koV_L68ysFSOp326bz5XilA_O9o3ollfwV8ixrR7ktgnkYJ36771mPyaTKeD4-8rlWDp5hINp5UYByKx0FGTHXMRRKa2NhQSQ2AIkuYgFhgkQlkqgJu8UdgEoBWJbcsEZllT8hh3dTmKaGCy0CIlAVGaa457LChSCOmMW4yEfXI263PimWryFFAJYNuLq67uUfeo0N3a1BH2w00qy9F56Yi1CWkaxOmiQm4MlJaHqKiW2yzsIy57pFkLxz23rY_A1Hg1Lk7rz_7552vye18NCmOp7MPz8mdCDk0Ad4bfEEON6sL85IcrPXFKxfufwCwvQik |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Design+and+Evaluation+of+223Ra-Labeled+and+Anti-PSMA+Targeted+NaA+Nanozeolites+for+Prostate+Cancer+Therapy%E2%80%94Part+II.+Toxicity%2C+Pharmacokinetics+and+Biodistribution&rft.jtitle=International+journal+of+molecular+sciences&rft.au=Lankoff%2C+Anna&rft.au=Czerwi%C5%84ska%2C+Malwina&rft.au=Walczak%2C+Rafa%C5%82&rft.au=Karczmarczyk%2C+Urszula&rft.date=2021-05-27&rft.pub=MDPI&rft.eissn=1422-0067&rft.volume=22&rft.issue=11&rft_id=info:doi/10.3390%2Fijms22115702&rft_id=info%3Apmid%2F34071854&rft.externalDBID=PMC8198605 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1422-0067&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1422-0067&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1422-0067&client=summon |